loperamidi hydrochloridum - תוצאות חיפוש

novartis israel ltd - glycopyrronium as bromide; indacaterol as acetate; mometasone furoate - קפסולה קשיחה - mometasone furoate 160 mcg; glycopyrronium as bromide 50 mcg; indacaterol as acetate 150 mcg - mometasone

ישראל - עברית - Ministry of Health

זנטק סירופ

glaxo smith kline (israel) ltd - ranitidine as hydrochloride - סירופ - ranitidine as hydrochloride 150 mg / 10 ml - ranitidine - ranitidine - h2 receptor antagonist. for treatment of duodenal ulcer and benign gastric ulcer, including that associated with nsaid agents. post-operative ulcer, oesophageal reflux disease and zollinger-ellison syndrome. prophylaxis of stress ulceration in seriously ill patients. before general anaesthesia in patients considered to be of risk acid aspiration (mendelson's syndrome).

ישראל - עברית - Ministry of Health

זופרן זריקות 2 מגמל

novartis israel ltd - ondansetron as hydrochloride dihydrate - תמיסה להזרקה - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:zofran is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

ישראל - עברית - Ministry of Health

אונדנסטרון אינובמד להזרקה 2 מ"ג/מ"ל

inovamed ltd - ondansetron as hydrochloride dihydrate 2 mg / 1 ml - solution for injection - ondansetron - adults:ondansetron inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron inovamed is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:ondansetron inovamed is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.